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INTRODUCTION
Cigarette smoking and asthma are associated with poor
symptom control and impaired therapeutic responses to anti-
asthma drugs (1). In the developed world, approximately
25% of the general population currently smokes cigarettes
(2) and a further 25% are former smokers; the smoking rates
are similar among adults with asthma (3-5). Higher levels
of smoking are seen in patients with asthma who attend emer-
gency departments with exacerbations (4). Compared with
asthmatic nonsmokers, smokers with asthma have worse
symptom control (3), an accelerated decline in lung function
(6), and an increased mortality rate (7). Asthmatic smokers
have more severe asthmatic symptoms (2, 3), greater need
for rescue medications (8), and worse indices of health status
in comparison with asthmatics who have never smoked (8).
The effect of smoking on the metabolism of drugs such as
theophylline is well known, but recent study has reported that
smokers with asthma had a poor responsiveness to corticos-
teroids (9). More studies are needed to elucidate the smok-
ing-induced changes in lung function and airway inflamma-
tion that may result in changes in clinical variable outcomes.
However, an analysis of the association between smoking sta-
tus and asthma has not been fully performed in patients with
asthma. In the present study, we evaluated the relationship
between smoking status and clinical and therapeutic param-
eters in asthmatic patients.
MATERIALS AND METHODS
Subjects and study protocol
Subjects were recruited from the Asthma Genome Research
Center of Soonchunhyang University Hospital, Bucheon,
Korea. On the first day of the study, a clinical history was
obtained from each patient, using a physician-administered
questionnaire. Chest PA radiography, a Water’s view, allergy
skin prick tests, and spirometry, including bronchodilator
responses after the inhalation of two puffs containing 100 μ g
of aerosolized albuterol, were performed. Blood and sputum
were sampled for differential cell counts. On the second visit,
airway hyperresponsiveness (AHR) was measured in cases
with a forced expiratory volume in 1 sec (FEV1) % predicted
of 70% or greater. All patients showed airway reversibility,
as documented by an inhalant bronchodilator-induced im-
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The Impact of Smoking on Clinical and Therapeutic Effects in 
Asthmatics
Smoking is associated with poor symptom control and impaired therapeutic res-
ponses in asthma. A total of 843 patients with asthma were recruited. The patients
received treatment for 1 yr according to the severity of their asthma. We compared
the forced expiratory volume in 1 sec (FEV1), the ratio of FEV1 to forced vital capaity
(FVC), atopy, total IgE, emphysema on high-resolution computed tomography
(HRCT), the number of near-fatal asthma attacks, and physiological fixed airway
obstruction between the smoking and nonsmoking groups. The study population
consisted of 159 (18.8%) current smokers, 157 (18.7%) ex-smokers, and 525 (62.5
%) nonsmokers. Although the prevalence of atopy was not different between the
smoking and nonsmoking groups, the total IgE was higher among the smokers
than the nonsmokers. Compared with the nonsmoking group, the smokers had a
lower FEV1 % predicted and forced expiratory flow between 25 and 75% of FVC.
A greater prevalence of emphysema and a significantly higher number of asthmat-
ic patients with fixed airway obstruction were detected in the smoking versus non-
smoking group. The 37.5% of asthmatic patients who were former or current smok-
ers showed decreased pulmonary function and increased IgE, emphysema on
HRCT, and fixed airway obstruction, indicating that smoking can modulate the clin-
ical and therapeutic responses in asthma.
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Accepted : 17 July 2008provement of more than 15% in FEV1, and/or airway hyper-
reactivity to less than 10 mg/mL of methacholine (10). The
asthmatic patients (N=843) with mild to severe symptoms
had comparable clinical symptoms and physical characteris-
tics, according to the Global Initiative for Asthma (GINA)
guidelines (11). Smoking status was assessed by the follow-
ing questions: 1) have you ever smoked cigarettes, with yes
or no response options. 2) do you smoke cigarettes now with
responses yes, no; 3) if not a current cigarette smoker, did you
smoke in the past 6 months; and From these questions a per-
son was assigned to be a current, ex-, or never-smoker. Sub-
jects were asked to record how many cigarettes they smoked.
The exclusion criteria included FEV1/forced vital capacity
(FVC) less than 70% and diffusing capacity less than 80%.
All subjects provided informed consent to participate in the
study, and the protocols were approved by the local ethics
committee.
Study intervention
Study patients received anti-asthma drugs according to their
asthma severity for 1 yr, based on the GINA guidelines (11).
The patients received long-term control medication consist-
ing of inhaled glucocorticoids, inhaled glucocorticoids plus
long-acting inhaled β 2-agonists, sustained-release theophy-
lline, a leukotriene modifier, or oral glucocorticoids, accord-
ing to GINA guidelines (11). Patients also received rapid-
relief medication consisting of two puffs of inhaled salbuta-
mol (100 μ g/dose) and two puffs of inhaled ipratropium bro-
mide (20 μ g/dose), as needed.
Fixed airway obstruction (11) as a functional marker of
airway remodeling was defined as both FEV1/FVC and pre-
dicted FEV1 of less than 75% when patients with asthma had
controlled status after anti asthma treatment for 1 yr accord-
ing to GINA guidelines. We assessed the effects of emphy-
sema by chest radiography or high-resolution computed
tomography (HRCT) and recorded the number of near-fatal
asthma attacks during the 1-yr anti-asthma treatment. Em-
physema (12) was defined as a focal area of very low attenu-
ation, usually without definable wall, that was surrounded
by higher attenuation normal lung parenchyma. Near-fatal
asthma was defined as the admission of a patient with asth-
ma to ward or an intensive care unit due to acute respiratory
failure matching the following criteria: the presence of hyper-
capnia (PaCO2, >45 mmHg) and signs of hypoxia (cyanosis
or PaO2, <60 mmHg) with a duration of exacerbation of less
than 7 days, according to GINA guidelines (13). During the
initial 7 days of treatment for near-fatal asthma, steroids (pred-
nisolone 2 mg/kg/day or an equivalent dose of methylpred-
nosone) and aminophylline (5 mg/kg/day) were administered
intravenously with concomitant inhalation of an aqueous β 2-
agonist (salbutamol) as needed. On the 7th day of treatment,
the systemic steroid was replaced with an inhaled steroid.
Lung function tests
Baseline FVC and FEV1 measurements were obtained in
the absence of recent bronchodilator use (within 8 hr) accord-
ing to the American Thoracic Society criteria (14). Basal and
post-bronchodilator FEV1, FVC, and forced expiratory flow
between 25% and 75% FVC (FEF25-75%) were measured
between 1:00 and 4:00 pm. AHR was measured using the
methacholine challenge test and was expressed as the provo-
cation concentration that caused a fall in the FEV1 of 20%
(PC20), in non-cumulative units (15).
Sputum examination
Sputum was induced using isotonic saline that contained
a short-acting bronchodilator, as described by Norzila et al.
(16). The samples were treated within 2 hr of collection, accord-
ing to the method of Pizzichini et al. (17) with a minor mod-
ification. Briefly, all visible portions with greater solidity were
carefully selected and placed in a pre-weighed Eppendorf
tube. The samples were treated by adding eight volumes of
0.05% dithiothreitol (Sputolysin; Calbiochem Corp., San
Diego, CA, U.S.A.) in Dulbecco’s phosphate-buffered saline
(D-PBS). One volume of protease inhibitors (0.1 M EDTA
and 2 mg/mL phenylmethylsulfonylfluoride) was added to
100 volumes of the homogenized sputum, and the total cell
count was determined with a hemocytometer. The cells of
the homogenized sputum were collected by cytocentrifuga-
tion, and 500 cells were examined on each sputum slide after
staining with Diff-Quick (American Scientific Products,
Chicago, IL, U.S.A.).
IgE measurements and allergy skin tests
Total IgE was measured using a UniCAP system (Pharma-
cia Diagnostics, Uppsala, Sweden). Allergy skin prick tests
were performed using commercially available inhalant aller-
gens, which included dust mites (Dermatophagoides farinae
and D. pteronyssinus, Bencard Co., Devon, U.K.) and his-
tamine (1 mg/mL). None of the subjects had received oral
antihistamines during the 3 days preceding the study. All of
the tests included positive (1 mg/mL histamine) and nega-
tive (diluent) controls. After 15 min, the mean diameter of
the wheals formed by the allergens (A) was compared with
that formed by histamine (H). If the former was the same or
larger than the latter (A/H ratio, ≥1.0), the reaction was
deemed positive. Atopy was determined by the presence of
an immediate skin reaction to one or more aeroallergens, as
previously described (18). 
Statistical analysis
Group differences were compared using a two-sample t-
test, Wilcoxon rank-sum test, or Pearson’s chi-square test for
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ly. A p value of less than 0.05 was considered significant.
RESULTS
Demographic profiles of the study subjects
Descriptive statistics of the asthmatic patients by smok-
ing status are shown in Table 1. The study population includ-
ed 159 (18.8%) current smokers (cigarette smoking history,
23.9±4.0 pack-years), 157 (18.7%) ex-smokers (cigarette
smoking history, 23.4±3.7 pack-years), and 525 (62.5%)
nonsmokers (Table 1). The ratio of males to females was high-
er among smokers than nonsmokers (males/females; 171/45
vs. 87/440, p<0.001).
Comparison of IgE and atopy by smoking status 
Although the prevalence of atopy was not different bet-
ween the smoking and nonsmoking groups, the total IgE
was higher in the smoking group (272.2±25.4 vs. 129.0
±13.0 U/L, p=0.006, Table 1).
Comparison of pulmonary function and severity of 
asthma by smoking status 
Compared with the nonsmoking group, the smoking group
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No. of subjects
Never-smokers
527
Current smokers
159
Ex-smokers
157
p value
Never-smokers
vs. smokers
Never-smokers
vs.
current-smokers
Current-
smokers vs.
ex-smokers
Age (yr) 47.8±0.71 46±1.07 50.8±1.25 NS NS 0.004
Sex (male/female) 87/440 135/24 136/21 0.001 0.001 NS
Duration of asthma (yr) 6.56±0.72 6.60±0.72 5.99±0.67 NS NS NS
FVC %, predicted  84.4±1.66 80.3±1.66 83.1±4.08 NS 0.029 NS
FEV1%, predicted  84.3±0.96 76.4±2.02 74.1±2.12 0.001 0.001 NS
PC20, methacholine (mg/mL) 8.47±0.83 5.71±1.11 7.63±1.23 NS 0.05 NS
Total IgE (IU/mL) 129.0±13.0 272.4±25.2 427.2±50.5 0.006 0.024 NS
Sputum eosinophil (%) 2.3±0.1 (0-12.6) 4.72±0.58 4.79±1.23 NS NS NS
Positive skin test (%) 206 (39.0) 74 (46.5) 61 (38.8) NS NS NS
Table 1. Clinical profiles of the study subjects
Plus-minus values are mean±S.E.
NS, not significant; NC, normal contols; PC20 methacholine, the concentration of methacholine required to decrease the FEV1 by 20%; FEV1, forced
expiratory volume in one second; FVC, forced vital capacity.
*Emphysema was defined as a focal area of very low attenuation, usu-
ally without definable wall, that was surrounded by higher attenuation
normal lung parenchyma. Near-fatal asthma* was defined as the admis-
sion of a patient with asthma to ward or an intensive care unit due to
acute respiratory failure matching the following criteria: the presence of
hypercapnia (PaCO2, >45 mmHg) and signs of hypoxia (cyanosis or
PaO2, <60 mmHg) with a duration of exacerbation of less than 7 days,
according to GINA guidelines. Fixed airway obstruction* as a functional
marker of airway remodeling was defined as both FEV1/FVC and pre-
dicted FEV1 of less than 75% when patients with asthma had controlled
status after anti asthma treatment for 1 yr according to GINA guidelines.
Smoking status  Significance
Emphysema on HRCT*
Yes Smoker: 12/60 (20%) p=0.006
No Non-smoker: 4/76 (5.2%)
Near fatal asthma*
Yes Smoker: 6/314 NS
No Non-smoker: 9/529
Fixed airway obstruction*
Yes Smoker:  41/314 p=0.001
No Non-smoker: 53/529
Table 2. Comparison of emphysema on HRCT, airway remod-
eling, and near fatal asthma attack by smoking status (χ 2 test)
400
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200
100
Smoking status
Severe Moderate Mild
Asthma severity
Ex
Current Never
0
55/34/68 42/34/83
75/117/335
Fig. 1. Asthma severity according to smoking status.
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rhad lower FEV1 % predicted (Table 1) and FEF25-75%
(34.2±2.2% vs. 72.9±1.6%, p<0.001). The proportion
of asthmatic patients with severe symptoms was higher in
the smoking than the nonsmoking group (exsmokers [mild/
moderate/severe] vs. current smokers vs. nonsmokers: 42/34/
83 vs. 55/34/68 vs. 75/117/335, p<0.01, Fig. 1).
Comparison of emphysema on HRCT and fixed airway
obstruction by smoking status 
There was no difference in the proportion of near-fatal
asthma attacks between the smokers and nonsmokers (Table
2). Emphysema was detected more often in the smoking
than the nonsmoking group (12/60 vs. 4/76, p=0.001, Table
2). The proportion of asthmatic patients with fixed airway
obstructions defined as the FEV1/FVC and FEV1 both of
less than 75% following anti-asthma treatment were signif-
icantly higher in the smoking group than in the nonsmok-
ing group (41/314 vs. 53/555, p=0.001, Table 2). 
DISCUSSION
In this study, we observed that smoking was associated
with asthma severity, decreased pulmonary function, and
increased total IgE, emphysema on HRCT, and fixed airway
obstruction. 
The rate of smoking has been reported to be similar bet-
ween adults with and without asthma, and the smoking rate
in our study (18.8%) was similar to these previously report-
ed rates (3, 5). The smoking rate was higher among males
than females in our study population.
The morbidity and mortality from asthma are both inc-
reased in patients who smoke cigarettes compared with pa-
tients who have never smoked (2). 
Asthmatic smokers have more severe asthmatic symptoms
(2, 3), a greater need for rescue medication (8), and worse
indices of health status compared with subjects who have
never smoked (8). Smoking a cigarette can cause acute bron-
choconstriction, although tobacco smoke does not act as an
acute irritant in all patients (19). The baseline FEV1 is direct-
ly related to the immediate response to inhaling cigarette
smoke (20), suggesting that asthmatic smokers with poorer
lung function may be particularly susceptible to the acute
effect of tobacco smoke. In our study, asthmatic patients who
smoked had a lower FEV1 than those who did not smoke,
suggesting that smokers with asthma have poorer lung func-
tion.
Visits to an emergency department as a result of exacerba-
tions of asthma occur more frequently among heavy cigarette
smokers with asthma following days with high levels of am-
bient ozone pollution (21). Hospital admission rates for asth-
ma and hospital-based care are increased in smokers (22),
although possibly not in younger adults (23). There is con-
flicting evidence as to whether current smoking is a risk fac-
tor for near-fatal or fatal asthma episodes (24). Nevertheless,
the 6-yr mortality rate is higher for smokers than nonsmok-
ers following a near-fatal asthma attack, with an age-adjust-
ed odds ratio (95% confidence interval [CI]) of 3.6 (2-6.2)
(25). In the present study there was no difference in the pro-
portion of near-fatal asthma attacks between the smokers and
nonsmokers, suggesting that smoking is not the only risk
factor for near-fatal asthma. A further long-term study in a
large population is necessary to clarify this effect of smoking. 
The combination of cigarette smoking and asthma accel-
erates the decline in lung function that occurs with either
factor alone (26). In one study, the combination of asthma
and smoking had a synergistic effect on the decline in lung
function, resulting in a 17.8% decline in FEV1 over 10 yr
(26). In our study, lung function, measured as the FEV1 pre-
dicted, FEF 25-75%, and FEV1/FVC, was lower in the smok-
ing group than those in the nonsmoking group, indicating
that smoking is an important factor for decreased lung func-
tion.
International guidelines on asthma management empha-
size inhaled corticosteroids as the most effective anti-inflam-
matory therapy for chronic asthma (13). The evidence for
this recommendation is based on clinical studies conducted
largely in asthmatic patients who have never smoked or were
former smokers. Smokers with asthma can be resistant to the
beneficial therapeutic effects of corticosteroids (9). Several
clinical factors might influence the response to corticosteroids
in asthmatic smokers (27, 28). The asthmatic smokers in
these studies had several clinical features that were distinct
from subjects with chronic obstructive pulmonary disease
(COPD) (27, 28). They were younger than subjects typical-
ly associated with symptomatic COPD (27, 28) and had a
long history of asthma. In addition, the patients had evidence
of bronchial hyperreactivity to methacholine (27) or reversibil-
ity following salbutamol of 15% (28). Among patients with
atopic asthma, smokers were less responsive to inhaled adeno-
sine than nonsmokers, which may indicate differences in air-
way inflammation (29). In the present study, the prevalence
of emphysema and functional airway remodeling was higher
in the smoking group than in the nonsmoking group, sug-
gesting that emphysema and fixed airway obstruction can
influence the response to anti-asthmatic drugs, including cor-
ticosteroids, in asthmatic smokers. The potential mechanisms
of corticosteroid resistance in asthmatic smokers are largely
unstudied but may include one or more of the pathways impli-
cated in nonsmokers with asthma or other inflammatory dis-
eases. Alternative treatments or treatments in addition to
inhaled corticosteroids may be required for asthmatic patients
who are unable to stop smoking or who have persistent symp-
toms following smoking cessation (30).
Cigarette smoking may change the airway inflammation
associated with asthma. Cigarette smoking has been shown
to induce airway inflammation in non-asthmatic smokers
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32). Normal smokers have shown increased T-lymphocytes,
mainly CD8 cells (30) and macrophages, within the airway
wall; higher neutrophil numbers within bronchial secretions;
and infiltration of peripheral airways with mononuclear cells
and macrophages (31). Sputum interleukin (IL)-8 levels were
increased in asthmatic smokers; the concentrations were posi-
tively related to the neutrophil proportions in sputum and
smoking history in pack-years and were negatively correlat-
ed with the FEV1 % predicted (30). In the present study,
there were no differences in the numbers of sputum eosino-
phils and neutrophils between smoking and nonsmoking
asthmatic patients. Cell and tissue sampling of lung using
bronchoalveolar lavage, and lung biopsy in addition to non-
invasive studies including exhaled nitric oxides for evalua-
tion of the role of airway inflammatory cells is needed. 
Smoking was found to alter the IgE response and increase
the sensitization to allergens in an animal model (32). In the
present study, although the prevalence of atopy was not dif-
ferent between the smoking and nonsmoking groups, the
total IgE was higher in the smoking than the nonsmoking
group, suggesting that smoking may influence IgE secretion
from B cells. The underlying mechanism of this effect has
not been clarified.
In conclusion, the 37.5% of asthmatic patients in this study
who were ex or current smokers showed decreased pulmonary
function and increased IgE levels, emphysema on HRCT,
and fixed airway obstruction, indicating that smoking can
modulate the clinical and therapeutic responses in asthma.
Future studies of adult asthma should consider the effects of
smoking on the clinical state and efficacy of therapy and inves-
tigate the related mechanisms. 
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